In vivo regulation of TGF-β by R-Ras2 revealed through loss of the RasGap protein NF1

Cancer Research

Volumn 72, Issue 20, 2012, Pages 5317-5327

  Patmore, Deanna M ^a   Welch, Sara ^a   Fulkerson, Patricia C ^a   Wu, Jianqiang ^a   Choi, Kwangmin ^a   Eaves, David ^a   Kordich, Jennifer J ^a   Collins, Margaret H ^a   Cripe, Timothy P ^a   Ratner, Nancy ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROFIBROMIN; PROTEIN KINASE B; R RAS2 PROTEIN; RAS PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BRAIN TUMOR; CANCER STEM CELL; CARCINOGENESIS; CELL COUNT; CELL SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE DELETION; IN VIVO STUDY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MOUSE; MYOFIBROBLAST; NEUROFIBROMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SARCOMA; SCHWANN CELL; TUMOR VOLUME;

ANIMALS; BLOTTING, WESTERN; HUMANS; MICE; NEUROFIBROMIN 1; RAS PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84867507362     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1972     Document Type: Article

References (48)

1. Mitin N, Rossman KL, Der CJ. Signaling interplay in Ras superfamily function. Curr Biol 2005;15:R563-74. (Pubitemid 41026614)
2. Castellano E, Downward J. Role of RAS in the regulation of PI 3-kinase. Curr Top Microbiol Immunol 2010;346:143-69.
3. Karnoub A, Weinberg R. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008;9:517-31. (Pubitemid 351881844)
4. Quinlan M, Quatela S, Philips M, Settleman J. Activated Kras, but Not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol Cell Biol 2008;28:2659-74.
5. Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer 2011;2:344-58.
6. Graham S, Oldham S, Martin C, Drugan J, Zohn I, Campbell S, et al. TC21 and Ras share indistinguishable transforming and differentiating activities. Oncogene 1999;18:2107-16.
7. Chan A, Miki T, Meyers K, Aaronson S. A human oncogene of the RAS superfamily unmasked by expression cDNA cloning. Proc Natl Acad Sci U S A 1994;91:7558-62. (Pubitemid 24238224)
8. Kim R, Trubetskoy A, Suzuki T, Jenkins NA, Copeland NG, Lenz J. Genome-based identi fication of cancer genes by proviral tagging in mouse retrovirus-induced T-cell lymphomas. J Virol 2003;77:2056-62. (Pubitemid 36110018)
9. Ohba Y, Mochizuki N, Yamashita S, Chan A, Schrader J, Hattori S, et al. Regulatory proteins of R-Ras, TC21/R-Ras2, and M-Ras/R-Ras3. J Biol Chem 2000;275:20020-6. (Pubitemid 30441610)
10. Boyd K, Korf B, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol 2009;61:1-14.
11. Evans D, Baser M, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis type1. J Med Genet 2002;39:311-4. (Pubitemid 34526349)
12. Huang Y, Rangwala F, Fulkerson PC, Ling B, Reed E, Cox AD, et al. Role of TC21/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells. Oncogene 2004;23:368-78. (Pubitemid 38174990)
13. Erdogan M, Pozzi A, Bhowmick N, Moses HL, Zent R. Signaling pathways regulating TC21-induced tumorigenesis. J Biol Chem 2007;282:27713-20. (Pubitemid 47529543)
14. Delgado P, Cubelos B, Calleja E, Martínez-Martín N, Ciprés A,Mérida I, et al. Essential function for the GTPase TC21 in homeostatic antigen receptor signaling. Nat Immunol. 2009;10:880-8.
15. Massagué J. TGFb in cancer. Cell 2008;134:215-30.
16. Yang L, Pang Y, Moses HL. TGFb and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010;31:220-7.
17. Rahimi R, Leof E. TGF-beta signaling: a tale of two responses. J Cell Biochem 2007;102:593-608. (Pubitemid 47557414)
18. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, et al. A mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasis. Cell 2009;137:87-98.
19. Lu S, Herrington H, Reh D, Weber S, Bornstein S, Wang D, et al. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev 2006;20:1331-42. (Pubitemid 43727593)
20. Kretzschmar M, Doody J, Timokhina I, Massagué J. A mechanism of repression of TGFb/Smad signaling by oncogenic Ras. Genes Dev 1999;13:804-16. (Pubitemid 29169840)
21. Lee M, Pardoux C, Hall M, Lee P, Warburton D, Qing J, et al. TGF-b activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO 2007;26:3957-67.
22. Grusch M, Petz M, Metzner T, Ozturk D, Schneller D, Mikulits W. The crosstalk of RAS with the TGF-β family during carcinoma progression and its implications for targeted cancer therapy. Curr Cancer Drug Targets 2010;10:849-57.
23. Geiser A, Kim S, Roberts A, Sporn M. Characterization of the mouse transforming growth factor-beta 1 promoter and activation by the Haras oncogene. Mol Cell Biol 1991;11:84-92. (Pubitemid 21895184)
24. Yue J, Mulder K. Requirement of Ras/MAPK pathway activation by transforming growth factor beta for transforming growth factor beta 1 production in a Smad-dependent pathway. J Biol Chem 2000;275:30765-73.
25. Cordenonsi M, Montagner M, Adorno M, Zacchigna L, Martello G, Mamidi A, et al. Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation. Science 2007;315:840-3.
26. Wu J, Williams J, Rizvi T, Kordich J, Witte D, Meijer D, et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert Hedgehog-expressing cells. Cancer Cell 2008;13:105-16. (Pubitemid 351163159)
27. Brannan C, Perkins A, Vogel K, Ratner N, Nordlund M, Reid S, et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 1994;8:1019-29. (Pubitemid 24145666)
28. Reilly K, Loisel D, Bronson R, McLaughlin M, Jacks T. NF1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 2000;26:109-13.
29. Williams J, Wu J, Johansson G, Rizvi T, Miller S, Geiger H, et al. Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neuro fibroma tumorigenic potential. Cell Stem Cell 2008;3:658-69.
30. Ghadimi M, Young E, Belousov R, Zhang Y, Lopez G, Lusby K, et al. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors. Clinical Cancer Res 2012;18:2545-57.
31. Frahm S, Mautner V, Brems H, Legius E, Debiec-Rychter M, Friedrich R, et al. Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients. Neurobiol Dis 2004;16:85-91. (Pubitemid 38569799)
32. Miller SJ, Rangwala F, Williams JP, Ackerman P, Kong S, Jegga A, et al. Large-scale molecular comparison of human Schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 2006;66:2584-91.
33. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med 2009;1:236-48.
34. Stemmer-Rachamimov A, Louis D, Nielsen G, Antonescu C, Borowsky A, Bronson R, et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res 2004;64:3718-24. (Pubitemid 38657953)
35. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006;312:117-21.
36. Arora S, Matta A, Shukla N, Deo S, Ralhan R. Identification of differentially expressed genes in oral squamous cell carcinoma. Mol Carcinog 2005;42:97-108.
37. Sharma R, Sud N, Chattopadhyay T, Ralhan R. TC21/R-Ras2 upregulation in esophageal tumorigenesis: potential diagnostic implications. Oncology 2005;69:10-8. (Pubitemid 41207053)
38. Hagedorn L, Suter U, Sommer L. P0 and PMP22 mark a multipotent neural crest-derived cell type that displays community effects in response to TGF-beta family factors. Development 1999;126:3781-94. (Pubitemid 29440477)
39. Parkinson D, Dong Z, Bunting H, Whitfi eld J, Meier C, Marie H, et al. Transforming growth factor b (TGFb) mediates Schwann cell death in vitro and in vivo : examination of c-Jun activation, interactions with survival signals, and the relationship of TGFb-mediated death to Schwann cell differentiation. J Neurosci 2001;21:8572-85. (Pubitemid 33051455)
40. +/- mast cells induce neuro fibroma like phenotypes through secreted TGF-signaling. Hum Mol Genet 2006;15:2421-37.
41. D'Antonio M, Droggiti A, Feltri ML, Roes J, Wrabetz L, Mirsky R, et al. TGFbeta type II receptor signaling controls Schwann cell death and proliferation in developing nerves. J Neurosci. 2006;26:8417-27. (Pubitemid 44316170)
42. Kim H, DeClue J, Ratner N. cAMP-dependent protein kinase A is required for Schwann cell growth: interactions between the cAMP and neuregulin/tyrosine kinase pathways. J Neurosci Res 1997;49:236-47. (Pubitemid 27332722)
43. Kraniak J, Sun D, Mattingly R, Reiners JJ, Tainsky M. The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors. Mol Cell Biochem 2010;344:267-76.
44. Rahimi R, Leof E. TGFbeta versatility: PI3K as a critical mediator of distinct cell type and context specific responses. Cell Cycle 2009;8:1813-7.
45. Akhurst R, Derynck R. TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol 2001;11:S44-51.
46. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
47. Network CGA. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
48. Hölzel M, Huang S, Koster J, Øra I, Lakeman A, Caron H, et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010;142:218-29.